• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Dipeptidyl-peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis.

作者信息

Kaneko Shizuka, Onda Yoshiyuki, Sakamoto Soichiro, Okada Mutsumi, Anzai Naoyuki

机构信息

Department of Diabetes/Endocrinology/Metabolism Takatsuki Red Cross Hospital Takatsuki Osaka Japan.

Department of Hematology and Oncology Takatsuki Red Cross Hospital Takatsuki Osaka Japan.

出版信息

EJHaem. 2021 May 20;2(3):551-554. doi: 10.1002/jha2.229. eCollection 2021 Aug.

DOI:10.1002/jha2.229
PMID:35844718
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9176032/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d83/9176032/7cb77c3bd375/JHA2-2-551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d83/9176032/669ecaf0103f/JHA2-2-551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d83/9176032/7cb77c3bd375/JHA2-2-551-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d83/9176032/669ecaf0103f/JHA2-2-551-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8d83/9176032/7cb77c3bd375/JHA2-2-551-g002.jpg

相似文献

1
Dipeptidyl-peptidase 4 inhibitor increased and maintained platelet count in a patient with primary myelofibrosis.二肽基肽酶4抑制剂使一名原发性骨髓纤维化患者的血小板计数增加并维持在一定水平。
EJHaem. 2021 May 20;2(3):551-554. doi: 10.1002/jha2.229. eCollection 2021 Aug.
2
Administration of a dipeptidyl peptidase IV inhibitor enhances the intestinal adaptation in a mouse model of short bowel syndrome.给予二肽基肽酶-4 抑制剂可增强短肠综合征小鼠模型的肠道适应。
Surgery. 2011 Aug;150(2):217-23. doi: 10.1016/j.surg.2011.05.013. Epub 2011 Jun 30.
3
Dipeptidyl peptidase IV in angiotensin-converting enzyme inhibitor associated angioedema.血管紧张素转换酶抑制剂相关性血管性水肿中的二肽基肽酶IV
Hypertension. 2008 Jan;51(1):141-7. doi: 10.1161/HYPERTENSIONAHA.107.096552. Epub 2007 Nov 19.
4
Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.新型二肽基肽酶-4抑制剂替格列汀对银屑病的改善作用：两例报告
J Dermatol. 2015 Nov;42(11):1094-7. doi: 10.1111/1346-8138.12955. Epub 2015 May 28.
5
Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review.二肽基肽酶-4抑制剂作为2型糖尿病患者胰岛素治疗附加药物的疗效和安全性：一项综述
Diabet Med. 2014 Nov;31(11):1293-300. doi: 10.1111/dme.12561.
6
Dipeptidyl-peptidase-4 (DPP-4) inhibitor ameliorates 5-flurouracil induced intestinal mucositis.二肽基肽酶-4（DPP-4）抑制剂可改善 5-氟尿嘧啶引起的肠道黏膜炎。
BMC Cancer. 2019 Oct 29;19(1):1016. doi: 10.1186/s12885-019-6231-y.
7
Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study.二肽基肽酶-4抑制剂对2型糖尿病患者心脏和内皮功能的影响：一项初步研究。
Diab Vasc Dis Res. 2016 May;13(3):236-43. doi: 10.1177/1479164116629352. Epub 2016 Mar 18.
8
Dipeptidyl peptidase-4 inhibitors and cardiovascular and renal disease in type 2 diabetes: What have we learned from the CARMELINA trial?二肽基肽酶-4 抑制剂与 2 型糖尿病的心血管和肾脏疾病：我们从 CARMELINA 试验中学到了什么？
Diab Vasc Dis Res. 2019 Jul;16(4):303-309. doi: 10.1177/1479164119842339. Epub 2019 Apr 24.
9
Effect of dipeptidyl peptidase-4 inhibitor in patients undergoing bypass surgery.二肽基肽酶-4抑制剂在接受搭桥手术患者中的作用。
Asian Cardiovasc Thorac Ann. 2016 Nov;24(9):863-867. doi: 10.1177/0218492316677384. Epub 2016 Oct 26.
10
Dynamics of total volume of pancreatic α- and β -cells under the influence sulfonylureas and their combination with dipeptidyl peptidase-4 inhibitors.磺酰脲类药物及其与二肽基肽酶-4 抑制剂联合应用对胰腺 α-和 β-细胞总量的影响。
Endocrinol Diabetes Metab. 2021 Mar 18;4(3):e00238. doi: 10.1002/edm2.238. eCollection 2021 Jul.

本文引用的文献

1
Dipeptidyl Peptidase 4 Inhibition for Prophylaxis of Acute Graft-versus-Host Disease.二肽基肽酶 4 抑制预防急性移植物抗宿主病。
N Engl J Med. 2021 Jan 7;384(1):11-19. doi: 10.1056/NEJMoa2027372.
2
Inflammasome activation and regulation: toward a better understanding of complex mechanisms.炎性小体的激活与调控：迈向对复杂机制的更深入理解
Cell Discov. 2020 Jun 9;6:36. doi: 10.1038/s41421-020-0167-x. eCollection 2020.
3
Dipeptidyl peptidase 4 inhibitors and their potential immune modulatory functions.二肽基肽酶 4 抑制剂及其潜在的免疫调节功能。
Pharmacol Ther. 2020 May;209:107503. doi: 10.1016/j.pharmthera.2020.107503. Epub 2020 Feb 14.
4
Novel targets to cure primary myelofibrosis from studies on Gata1 mice.从 Gata1 小鼠研究中寻找治疗原发性骨髓纤维化的新靶点。
IUBMB Life. 2020 Jan;72(1):131-141. doi: 10.1002/iub.2198. Epub 2019 Nov 21.
5
Myeloproliferative Neoplasms.骨髓增殖性肿瘤
N Engl J Med. 2017 Aug 31;377(9):895-6. doi: 10.1056/NEJMc1708485.
6
Preclinical rationale for TGF-β inhibition as a therapeutic target for the treatment of myelofibrosis.转化生长因子-β（TGF-β）抑制作为骨髓纤维化治疗靶点的临床前理论依据。
Exp Hematol. 2016 Dec;44(12):1138-1155.e4. doi: 10.1016/j.exphem.2016.08.007. Epub 2016 Aug 31.
7
Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β.原发性骨髓纤维化中的骨髓纤维化：致病机制及转化生长因子-β的作用
Stem Cell Investig. 2016 Feb 26;3:5. doi: 10.3978/j.issn.2306-9759.2016.02.03. eCollection 2016.
8
A novel interaction between megakaryocytes and activated fibrocytes increases TGF-β bioavailability in the Gata1(low) mouse model of myelofibrosis.巨核细胞与活化纤维细胞之间的新型相互作用增加了骨髓纤维化Gata1（低）小鼠模型中转化生长因子-β（TGF-β）的生物利用度。
Am J Blood Res. 2015 Dec 25;5(2):34-61. eCollection 2015.
9
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.2016 年版世界卫生组织髓系肿瘤和急性白血病分类。
Blood. 2016 May 19;127(20):2391-405. doi: 10.1182/blood-2016-03-643544. Epub 2016 Apr 11.
10
Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system.切入正题：关于CD26/二肽基肽酶4（DPP4）在免疫系统中相互关系的综述
Clin Exp Immunol. 2016 Jul;185(1):1-21. doi: 10.1111/cei.12781. Epub 2016 May 13.